|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
|4.||Parkinson Disease (Parkinson's Disease)
|5.||Urge Urinary Incontinence (Urge Incontinence)
|1.||Chancellor, Michael B: 41 articles (12/2015 - 03/2002)|
|2.||Guan, Zhonghong: 36 articles (06/2012 - 04/2006)|
|3.||Cardozo, Linda: 32 articles (10/2015 - 12/2002)|
|4.||Kuo, Hann-Chorng: 32 articles (09/2015 - 06/2008)|
|5.||Sand, Peter K: 28 articles (04/2013 - 06/2003)|
|6.||Khullar, Vik: 27 articles (06/2015 - 07/2005)|
|7.||Dmochowski, Roger R: 26 articles (09/2015 - 08/2002)|
|8.||Kaplan, Steven A: 23 articles (06/2015 - 05/2006)|
|9.||Andersson, Karl-Erik: 21 articles (10/2015 - 01/2004)|
|10.||Michel, Martin C: 21 articles (06/2014 - 01/2002)|
|1.||tolterodine (Detrol)FDA Link
06/01/2006 - "We evaluated the efficacy of tolterodine extended release (ER) for patients' most bothersome overactive bladder (OAB) symptom in a primary care setting. "
01/01/2004 - "Based on the low frequency of adverse events, the absence of unexpected adverse events and the very low frequency of serious adverse events, we conclude that tolterodine is a well tolerated treatment for overactive bladder in adults, in whom it should be considered as first-line therapy."
04/01/2001 - "There was an improvement in voiding diary variables in all treatment groups after 2 weeks of treatment, although the efficacy was greatest in those taking 1 mg and 2 mg. Pharmacokinetic findings were consistent with dose linearity over the range 0.5-2 mg. The results support the use of 1 mg twice daily as the optimal dose of tolterodine for treating children aged 5-10 years with an overactive bladder."
05/01/2005 - "Favorable safety, tolerability and efficacy of once-daily tolterodine ER was maintained over 12 months in a Japanese overactive bladder patient population."
02/01/2003 - "A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder."
|2.||oxybutynin (Tavor)FDA LinkGeneric
07/01/2015 - "Intravesical oxybutynin is highly effective in the treatment of overactive bladder. "
01/01/2002 - "While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly dry mouth. "
03/01/1995 - "In summary, oxybutynin is one of the few drugs proven to be beneficial in some patients with overactive detrusor function. "
01/01/2011 - "In a recent placebo-controlled Phase III study, oxybutynin chloride topical gel (OTG) significantly improved urinary continence in patients with overactive bladder. "
01/01/2009 - "*In two well designed trials in patients with overactive bladder, transdermal oxybutynin 3.9 mg/day decreased the number of incontinence episodes and increased average voided volume to a significantly greater extent than placebo. "
|3.||quinuclidin- 3'- yl- 1- phenyl- 1,2,3,4- tetrahydroisoquinoline- 2- carboxylate monosuccinate (solifenacin)FDA Link
01/01/2012 - "In this post-hoc analysis of data from patients with overactive bladder (OAB) in VIBRANT patients receiving solifenacin showed statistically significantly greater improvement versus placebo in most outcome measures regardless of OAB symptom duration (less than five years and five years or longer)."
11/01/2004 - "In this study treatment with solifenacin 5 mg and 10 mg once daily significantly improved all the major symptoms of overactive bladder including frequency, urgency and incontinence. "
01/01/2015 - "Application of solifenacin at a dose of 5 mg in patients with overactive bladder significantly reduces the severity of symptoms. "
05/01/2014 - "Solifenacin also significantly improved the four quality of life subscales, total quality of life and symptom bother scores of the Overactive Bladder questionnaire. "
05/01/2014 - "Solifenacin significantly improved the total Overactive Bladder Symptom Score and also all subscores for the four symptoms (daytime frequency, urgency, night-time frequency and urgency incontinence). "
09/01/2014 - "If safe and effective therapy for UAB is made available, then most experts agree that the potential market would exceed industry expectations, just as antimuscarinic agents for overactive bladder did in the late 1990 s. "
01/01/2011 - "Antimuscarinics have proven efficacy as first-line therapy in overactive bladder (OAB); however, data on their use in older adults are needed. "
08/01/2005 - "Antimuscarinic agents, effective in relieving symptoms of overactive bladder, are associated with anticholinergic-mediated adverse events, particularly at high dosages. "
06/01/2012 - "Antimuscarinics, with or without an α-blocker, may be effective for the treatment of the storage symptoms of overactive bladder in some men. "
10/01/2010 - "Pharmacologic therapies (primarily antimuscarinic agents) have been the mainstay of treatment for overactive bladder. "
01/01/2011 - "Fesoterodine, a new once daily antimuscarinic, has proven to be an effective, safe, and well-tolerated treatment in patients with overactive bladder (OAB). "
07/01/2008 - "In clinical studies both doses of fesoterodine were consistently superior to placebo in improving the symptoms of overactive bladder syndrome, with 8 mg/day having significantly greater effects than 4 mg/day."
08/01/2012 - "• Long-term fesoterodine treatment was associated with sustained improvement in measures of health-related quality of life and bladder-related problems and with high treatment satisfaction in subjects with overactive bladder symptoms. "
06/01/2012 - "Flexible-dose fesoterodine as an add-on treatment significantly improved urinary frequency and symptom bother, but not urgency episodes (primary endpoint), versus add-on placebo and was well tolerated in men with persistent overactive bladder symptoms despite receiving α-blocker. "
12/01/2007 - "The 2 doses of fesoterodine were well tolerated and they statistically significantly improved overactive bladder symptoms."
|6.||Botulinum Toxins (Botulinum Toxin)IBA
12/01/2013 - "We evaluated whether patients with overactive bladder and incontinence who discontinued intravesical botulinum toxin therapy can be successfully treated with sacral neuromodulation. "
01/01/2011 - "In urology, botulin is effective in overactive bladder and incomplete voiding."
01/01/2007 - "Botulinum toxin B is not an effective treatment of refractory overactive bladder."
01/01/2006 - "Botulinum toxin is not yet approved by the US Food and Drug Administration for the treatment of detrusor overactivity and overactive bladder, but the positive results seen thus far cannot be ignored."
02/01/2012 - "To evaluate the efficacy of intradetrusor botulinum toxin-A (BTX-A) in idiopathic overactive bladder patients (OAB) refractory to anti-muscarinic therapy, without detrusor overactivity (DOA) on urodynamics. "
|7.||Cholinergic Antagonists (Anticholinergics)IBA
06/01/2011 - "Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. "
06/01/2011 - "Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. "
01/01/2012 - "During initial treatment of overactive bladder syndrome there was more symptomatic improvement when (a) anticholinergics were compared with bladder training alone, and (b) anticholinergics combined with bladder training were compared with bladder training alone. "
02/01/2006 - "Conservative therapy (especially oral anticholinergic agents) in children with overactive bladder is effective when applied appropriately (especially in patients with evident detrusor instability) with adequate follow up. "
09/01/2005 - "There is a lack of study on efficacy of apha-1 blocker administration combined with anticholinergics available in our hands for patients with BPH and overactive bladder. "
|8.||onabotulinumtoxinA (Botox)FDA Link
06/01/2015 - "This meta-analysis indicates that onabotulinumtoxinA to be an effective treatment for idiopathic overactive bladder symptoms with side effects primarily localized to urinary tract."
01/01/2012 - "Botox) provides effective treatment for overactive bladder. "
01/01/2014 - "OnabotulinumtoxinA injection is a safe and effective treatment for adults with refractory overactive bladder. "
09/01/2011 - ": The objective of the study was to evaluate the safety and efficacy of repeat intradetrusor onabotulinum toxin A injection in patients with idiopathic overactive bladder refractory to anticholinergic medications. "
11/01/2015 - "Here we present the final results from an extension study assessing long-term onabotulinumtoxinA treatment (3.5 years) in patients with idiopathic overactive bladder. "
|9.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA
03/01/2009 - "Muscarinic receptor antagonists are effective in the treatment of overactive bladder (OAB), but their site(s) of action and actual therapeutic target are unclear. "
10/01/2007 - "Muscarinic receptor antagonists are effective for treatment of the overactive bladder. "
03/01/2006 - "Muscarinic receptor antagonists have been reported to be effective in the treatment of overactive bladder. "
05/01/2000 - "A wealth of clinical evidence supports the view that muscarinic receptor antagonists are effective in the treatment of overactive bladder. "
02/01/2015 - "The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study."
|10.||tamsulosin (Flomax)FDA LinkGeneric
03/01/2015 - "Combined tamsulosin and mirabegron treatment is effective and safe for patients with benign prostatic obstruction who have overactive bladder symptoms after tamsulosin monotherapy."
08/01/2015 - "Re: A Randomized Controlled Study of the Efficacy of Tamsulosin Monotherapy and its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Obstruction: K. "
03/01/2015 - "A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction."
03/01/2015 - "Percentage of patients with relative prevalence of symptoms of overactive bladder slightly increases against administration of Tamsulosin and reaches initial values at the time of administration of anti-muscarinic drugs with absolute decrease in number of such patients. "
03/01/2015 - "We evaluated the efficacy and safety of add-on treatment with a β3-adrenoceptor agonist (mirabegron) for overactive bladder symptoms remaining after α1-blocker (tamsulosin) treatment in men with benign prostatic obstruction. "
01/01/2010 - "Mean bladder volume increased from 137 to 396 ml. Non-neurogenic overactive bladder: of 7 injections, 6 (85.7%) were judged effective in 5 patients. "
07/01/2008 - "Intradetrusor BTA injections are an effective and well tolerated treatment for neurogenic overactive bladder. "
03/01/2006 - "Bladder injections with BONT-A are effective for not only neurogenic detrusor overactivity but also overactive bladder. "
01/01/2005 - "Bladder injections with BTX-A are effective for not only neurogenic detrusor overactivity, but also overactive bladder. "
07/01/2008 - "Limited studies to date have reported on the onset of effect of intradetrusor botulinum neurotoxin type A (BoNTA) injections when used to treat the symptoms of the overactive bladder (OAB). "
|2.||Drug Therapy (Chemotherapy)
01/01/2006 - "The efficacy of antimuscarinic drug therapy in patients who have more severe symptoms of overactive bladder (OAB) at baseline has not been evaluated thoroughly. "
09/01/2015 - "As a result behavioral interventions are considered to be effective in controlling symptoms of an overactive bladder; in some studies an additive effect to drug therapy is seen if behavioral interventions are performed as supplementary measure; other studies could not confirm such an effect. "
09/01/2009 - "Pharmacotherapy is the mainstay of treatment for overactive bladder. "
11/01/2006 - "Pharmacotherapy is the first-line treatment for overactive bladder, but many patients discontinue drug therapy because of intolerable side effects, expense, or lack of longterm adherence. "
05/01/2013 - "The aim of the study was to describe effectiveness and safety of percutaneous tibial nerve stimulation (PTNS) at 2 years in women with overactive bladder (OAB) syndrome unresponsive to pharmacotherapy. "
03/01/2012 - "This study's aim was to assess the use of intravesical injection of botulinum neurotoxin type A (BoNT-A) as a treatment of overactive bladder (OAB) in children. "
04/25/2012 - "In patients with refractory overactive bladder, the intravesical injection of botulinum neurotoxin is available."
11/01/2005 - "Intravesical instillation therapy can provide an alternative treatment for the management of overactive bladder."
01/01/2013 - "These findings suggest that an intravesical injection of H2O2 induces relatively long-lasting inflammatory and overactive bladder, compared with existing cystitis models. "
01/01/2014 - "Intravesical injection of onabotulinumtoxinA is an effective treatment for overactive bladder (OAB). "
|4.||Transcutaneous Electric Nerve Stimulation (TENS)
08/01/2013 - "We found that parasacral transcutaneous electrical nerve stimulation is more effective in resolving overactive bladder symptoms, which matches parental perception. "
10/01/2013 - "Transcutaneous electrical nerve stimulation: an effective treatment for refractory non-neurogenic overactive bladder syndrome?"
08/01/2010 - "This is the first known randomized clinical trial to demonstrate that parasacral transcutaneous electrical nerve stimulation is effective in the treatment of children with overactive bladder."
09/01/2015 - "The purpose of this study was to evaluate safety and tolerability of transcutaneous tibial nerve stimulation (TENS) in patients under 15years of age with refractory overactive bladder. "
07/01/2015 - "The aim of the study was to evaluate the acute effect of transcutaneous electrical nerve stimulation (TENS) on rectal motility in children with overactive bladder (OAB). "
|5.||Psychology Biofeedback (Biofeedback)
01/01/2004 - "To compare the efficacy of pelvic floor muscle training (PFMT), biofeedback-assisted PFMT (BAPFMT), and electrical stimulation (ES) in the management of overactive bladder (OAB). "
03/01/2005 - "Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder."
01/01/2004 - "Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder."
08/17/2015 - "Feedback and biofeedback training can be used to treat an overactive bladder. "
04/01/2015 - "To evaluate and compare the effectiveness of biofeedback therapy (BF) in children with treatment refractory overactive bladder (OAB) and dysfunctional voiding (DV). "